COVID-19

Without a doubt, preparedness for future disasters is primary, but images of deserted streets and highways prompt another take.
Mark Twain famously said, "What gets us into trouble is not what we don't know. It's what we know for sure that just ain't so."
Press briefings, by any measure, are long and loud. And now they may get longer and louder since there is another potential antiviral drug to yell about. 
COVID-19 continues to dominate my reading. While we cannot control the underlying sources and drivers of a pandemic, we can control our response. The literature, mainstream and professional, is beginning to reflect on our response.
Among the many lessons of the COVID-19 pandemic is how cumbersome one‐​size‐​fits‐​all regulations, administered by an impersonal bureaucracy, hamper a rapid and flexible response to an evolving public health emergency. The U.S.
Since the start of social distancing (March 16, 2020) mobility in the United States has dropped 49% Every US state has reduced mobility. Early adopters are doing better than late or non-adopters.
There has been a lot of confusion in regard to possible treatments for COVID-19 and the timeline for the development and deployment of those treatments.
Let me get you "up to speed" with some context.